$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
CTCs represent a key step of cancer cell dissemination1. Their presence in the peripheral blood of patients is associated with (metastatic) relapse and disease progression2,3. CTC isolation and characterization from the blood of cancer patients is a type of non-invasive liquid biopsy. In recent years, it has become increasingly evident that monitoring the progression and response of tumors to different treatments using this kind of analysis provides important clinical information4,5. Liquid biopsy is even more useful when surgery is not feasible or when primary tumor tissue is not available, i.e., for non-biopsiable lesions. Hence, this approach is promising in specific cancer settings such as metastatic NSCLC, where the presence of CTCs has been shown to have a negative prognostic role6. NSCLC is a tumor that benefits especially from targeted therapeutic approaches7,8,9 designed to act on specific molecules (molecular targets) known to be involved in the growth, progression, and spread of the disease. Hence, the detection of specific targets during disease progression is needed. CTC investigation is an extremely interesting diagnostic approach to detect and monitor drug targets without the need for primary or metastatic tissues. For example, the detection of ALK gene translocations in NSCLC cells is associated with sensitivity to crizotinib, a specific targeted therapy10. However, at present, the detection of ALK translocations is executed only on fine-needle aspirates or small biopsies; as a result, without a tumor tissue ALK analysis is not possible. CTCs are a potential alternative to tumor tissue-based investigations and represent a highly promising companion diagnostic approach.
Despite their potential importance, CTCs are still a subject of great debate among research, mainly because of their rarity (1-10 cells/mL of peripheral blood11). Current liquid biopsy methods use a limited amount of blood (i.e., 1-30 mL)12,13, but this creates a situation of suboptimal sensitivity for the detection of CTCs. Hence, research is warranted to finding approaches and developing devices to perform CTC-targeted liquid biopsies on a larger volume of peripheral blood.
An alternative device, a functionalized medical wire (see Table of Materials), has been developed to overcome blood sampling limitations and obtain a more representative analysis of CTCs. This functionalized wire is a CE-approved medical device that captures CTCs directly from the bloodstream of cancer patients1. It is composed of a 16-cm-long stainless steel wire (Figure 1a) with a 2-cm-long functionalized tip coated with a 0.2-µm-thick layer of gold. The layer is in turn covered by a 1 to 5 µm-thick polycarboxylate hydrogel stratum covalently coupled with antibodies directed against the EpCAM, one of the most widely expressed antigens on the surface of CTCs14. The functionalized tip of the wire is introduced into a vein of the arm of the patient and remains in position for at least 30 min. This approach allows isolation of CTCs in vivo, directly in peripheral blood, and to screen about 1.5-3.0 L of blood (approximately 300-fold more than the volume used for alternative approaches)1.
Pantel et al. demonstrated the efficacy of this approach in isolating CTCs directly into the arm veins of lung cancer patients15. They performed wire immunofluorescence staining to identify CTCs using conventional antibodies directed against EpCAM and pan-cytokeratin, and CD45 for leucocyte detection. The wire was examined under an optical fluorescence microscope15. The authors demonstrated that the device was able to isolate CTCs, but they did not investigate any therapy-related targets, such as ALK translocations.
The presented method aims to identify putative CTCs in NSCLC cell lines on the basis of phenotypical parameters, e.g., EpCAM positivity and the presence of molecular biomarkers, for instance the ALK status (Figure 1b). This 3-day-long procedure combines a functionalized wire and immunofluorescence staining with DNA fluorescence-in-situ-hybridization (DNA FISH), named Immuno-DNA-FISH. Given that CTCs are rare entities, the advantage of this protocol is that CTCs can be characterized on the same wire in terms of both immunophenotypic features and DNA rearrangements.